Dexrazoxane Exposure and Risk of Secondary Acute Myeloid Leukemia in Pediatric Oncology Patients

BACKGROUND: Dexrazoxane may reduce anthracycline-associated cardiotoxicity in pediatric cancer patients. However, concerns of secondary acute myeloid leukemia (AML) have led to restrictions on pediatric dexrazoxane use in Europe. Published data about dexrazoxane-associated secondary AML are limited...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Seif, Alix E., Walker, Dana M., Li, Yimei, Huang, Yuan-Shung V., Kavcic, Marko, Torp, Kari, Bagatell, Rochelle, Fisher, Brian T., Aplenc, Richard
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4177031/
https://ncbi.nlm.nih.gov/pubmed/24668949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25043
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi